{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T17:57:53Z","timestamp":1793555873039,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>This study reported real-world visual acuity (VA), treatment patterns, and ocular safety outcomes from patients with macular oedema secondary to branch, central, or hemi-retinal vein occlusion (BRVO, CRVO, HRVO) treated with anti-vascular endothelial growth factor (VEGF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected from Medisoft electronic medical records across 16 NHS ophthalmology sites in England over 60 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>3511\/3465 eyes\/patients with BRVO and 3568\/3514 eyes\/patients with CRVO or HRVO were included; &lt;2% of patients had bilateral RVO and had both eyes included. VA change from index anti-VEGF treatment was lower with longer follow-up. In BRVO eyes, mean (95% CI) change in VA from index was +11.2 (10.6, 11.7) approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letters at Month (M)6 and +8.3 (6.7, 10.0) at M60. Mean (95% CI) change in VA for CRVO\/HRVO eyes was +11.5 (10.7, 12.3) approximate ETDRS letters at M6 and +7.0 (4.8, 9.2) at M60. Eyes receiving more injections displayed greater average VA gains. Median (Q1\u2013Q3) annual number of anti-VEGF injections was lower in BRVO and CRVO\/HRVO eyes with longer follow-up: M12, 7.0 (5.0\u20138.0) and 6.0 (4.0\u20138.0); M60, 2.0 (0.0\u20135.0) and 1.0 (0.0\u20135.0). Ocular safety outcome incidence through 60 months was low (endophthalmitis, retinal tears, and retinal detachment &lt;1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VA improvements were observed soon after anti-VEGF treatment, but were lower with longer follow-up through 60 months, alongside lower annual injection numbers, suggesting that current single-target intravitreal anti-VEGFs may not be sufficiently durable for long-term RVO management in routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04089-2","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T18:03:42Z","timestamp":1763143422000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-4771","authenticated-orcid":false,"given":"Christiana","family":"Dinah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8748-5299","authenticated-orcid":false,"given":"Melanie","family":"Dodds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5541-4305","authenticated-orcid":false,"given":"Andrew","family":"Lotery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-8661","authenticated-orcid":false,"given":"Alice V. R.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Paris Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Cecile","family":"Retiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insaf","family":"Saffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Arrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"United Kingdom Retinal Vein Occlusion Electronic Medical Records Users Group (UK RVO EMR Users Group)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Antcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruque","family":"Ghanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Talks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aires","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinka","family":"Osoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasubramanian","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"4089_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/eye.2011.92","volume":"25","author":"M Laouri","year":"2011","unstructured":"Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981\u20138.","journal-title":"Eye"},{"key":"4089_CR2","first-page":"335","volume":"36","author":"P Kalva","year":"2023","unstructured":"Kalva P, Akram R, Zuberi HZ, Kooner KS. Prevalence and risk factors of retinal vein occlusion in the United States: The National Health and Nutrition Examination Survey, 2005 to 2008. Proc (Bayl Univ Med Cent). 2023;36:335\u201340.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"4089_CR3","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9:010427.","journal-title":"J Glob Health"},{"key":"4089_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/APO.0000000000000598","volume":"12","author":"F Romano","year":"2023","unstructured":"Romano F, Lamanna F, Gabrielle PH, Teo K, Battaglia Parodi M, Iacono P, et al. Update on retinal vein occlusion. Asia Pac J Ophthalmol. 2023;12:196\u2013210.","journal-title":"Asia Pac J Ophthalmol"},{"key":"4089_CR5","first-page":"802936","volume":"13","author":"H Gong","year":"2022","unstructured":"Gong H, Rehman F, Ma Y, A B, Zeng S, Yang T, et al. A review of intraocular biomolecules in retinal vein occlusion: toward potential biomarkers for companion diagnostics. Front Pharm. 2022;13:802936.","journal-title":"Front Pharm"},{"key":"4089_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","volume":"36","author":"L Nicholson","year":"2022","unstructured":"Nicholson L, Talks SJ, Amoaku W, Talks K, Sivaprasad S. Retinal vein occlusion (RVO) guideline: executive summary. Eye (Lond). 2022;36:909\u201312.","journal-title":"Eye (Lond)"},{"key":"4089_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/2474126420906395","volume":"4","author":"YS Modi","year":"2020","unstructured":"Modi YS, Klufas MA, Sridhar J, Singh RP, Yonekawa Y, Pecen P. Current best clinical practices-management of retinal vein occlusion. J Vitreoretin Dis. 2020;4:214\u20139.","journal-title":"J Vitreoretin Dis"},{"key":"4089_CR8","doi-asserted-by":"publisher","first-page":"100964","DOI":"10.1016\/j.preteyeres.2021.100964","volume":"85","author":"SS Hayreh","year":"2021","unstructured":"Hayreh SS. Photocoagulation for retinal vein occlusion. Prog Retin Eye Res. 2021;85:100964.","journal-title":"Prog Retin Eye Res"},{"key":"4089_CR9","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/j.1538-7836.2010.03909.x","volume":"8","author":"M Rehak","year":"2010","unstructured":"Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 2010;8:1886\u201394.","journal-title":"J Thromb Haemost"},{"key":"4089_CR10","first-page":"353","volume":"101","author":"T Wecker","year":"2017","unstructured":"Wecker T, Ehlken C, B\u00fchler A, Lange C, Agostini H, B\u00f6hringer D, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101:353\u20139.","journal-title":"Br J Ophthalmol"},{"key":"4089_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939\u201346.","journal-title":"Clin Ophthalmol"},{"key":"4089_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/OPTH.S163859","volume":"12","author":"JM Jumper","year":"2018","unstructured":"Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophthalmol. 2018;12:621\u20139.","journal-title":"Clin Ophthalmol"},{"key":"4089_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.5301\/ejo.5000943","volume":"27","author":"S Vaz-Pereira","year":"2017","unstructured":"Vaz-Pereira S, Marques IP, Matias J, Mira F, Ribeiro L, Flores R. Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal. Eur J Ophthalmol. 2017;27:756\u201361.","journal-title":"Eur J Ophthalmol"},{"key":"4089_CR14","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30:1046\u201350.","journal-title":"Retina"},{"key":"4089_CR15","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing: R Foundation for Statistical Computing, 2024."},{"key":"4089_CR16","unstructured":"CADTH Common Drug Reviews. Aflibercept (Eylea): Treatment of Neovascular (Wet) Age-Related Macular Degeneration (wAMD). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015."},{"key":"4089_CR17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.visres.2010.05.021","volume":"50","author":"C Owsley","year":"2010","unstructured":"Owsley C, McGwin G Jr. Vision and driving. Vision Res. 2010;50:2348\u201361.","journal-title":"Vision Res"},{"key":"4089_CR18","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/eye.2016.149","volume":"30","author":"G Liew","year":"2016","unstructured":"Liew G, Lee AY, Zarranz-Ventura J, Stratton I, Bunce C, Chakravarthy U, et al. The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye. 2016;30:1462\u20138.","journal-title":"Eye"},{"key":"4089_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242:123\u201362.","journal-title":"Ophthalmologica"},{"key":"4089_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4274\/tjo.galenos.2021.09258","volume":"52","author":"P Kunavisarut","year":"2022","unstructured":"Kunavisarut P, Supawongwattana M, Patikulsila D, Choovuthayakorn J, Watanachai N, Chaikitmongkol V, et al. Idiopathic epiretinal membranes: visual outcomes and prognostic factors. Turk J Ophthalmol. 2022;52:109\u201318.","journal-title":"Turk J Ophthalmol"},{"key":"4089_CR21","first-page":"505","volume":"5","author":"YS Modi","year":"2021","unstructured":"Modi YS, Goduni L, Moini H, Gibson A, Boucher N, Lucas G, et al. Antivascular endothelial growth factor dosing frequency and visual outcomes in macular edema following central retinal vein occlusion. Journal Vitreoretina Dis. 2021;5:505\u201312.","journal-title":"Journal Vitreoretina Dis"},{"key":"4089_CR22","first-page":"1304","volume":"61","author":"RB Bhisitkul","year":"2020","unstructured":"Bhisitkul RB, Blotner S, Steffen V, Haskova Z. Clinical trial versus real-world outcomes with anti-VEGF therapy for central retinal vein occlusion. Investig Ophthalmol Vis Sci. 2020;61:1304\u20131304.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4089_CR23","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41433-020-0861-9","volume":"34","author":"JL Ang","year":"2020","unstructured":"Ang JL, Ah-Moye S, Kim LN, Nguyen V, Hunt A, Barthelmes D, et al. A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion. Eye. 2020;34:1770\u201396.","journal-title":"Eye"},{"key":"4089_CR24","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2015;122:1837\u201345.","journal-title":"Ophthalmology"},{"key":"4089_CR25","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1038\/s41433-022-02349-z","volume":"37","author":"E Preston","year":"2023","unstructured":"Preston E, Hamilton RD, Mahroo OA. Exploring regression to the mean in visual acuities by investigating measurements at two consecutive time points in untreated fellow eyes. Eye. 2023;37:2356\u20137.","journal-title":"Eye"},{"key":"4089_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamaophthalmol.2021.5619","volume":"140","author":"S Gurudas","year":"2022","unstructured":"Gurudas S, Patrao N, Nicholson L, Sen P, Ramu J, Sivaprasad S, et al. Visual outcomes associated with patterns of macular edema resolution in central retinal vein occlusion treated with anti\u2013vascular endothelial growth factor therapy: a post hoc analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) trial. JAMA Ophthalmol. 2022;140:143\u201350.","journal-title":"JAMA Ophthalmol"},{"key":"4089_CR27","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.xops.2023.100302","volume":"3","author":"LO Hattenbach","year":"2023","unstructured":"Hattenbach LO, Abreu F, Arrisi P, Basu K, Danzig CJ, Guymer R, et al. BALATON and COMINO: phase III randomized clinical trials of faricimab for retinal vein occlusion: study design and rationale. Ophthalmol Sci. 2023;3:100302.","journal-title":"Ophthalmol Sci"},{"key":"4089_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01757-7","volume":"21","author":"R Narayanan","year":"2021","unstructured":"Narayanan R, Kelkar A, Abbas Z, Goel N, Soman M, Naik N, et al. Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab. BMC Ophthalmol. 2021;21:33.","journal-title":"BMC Ophthalmol"},{"key":"4089_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V, et al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023;12:92.","journal-title":"Syst Rev"},{"key":"4089_CR30","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1136\/bjophthalmol-2017-311494","volume":"102","author":"K Kortuem","year":"2018","unstructured":"Kortuem K, Fasler K, Charnley A, Khambati H, Fasolo S, Katz M, et al. Implementation of medical retina virtual clinics in a tertiary eye care referral centre. Br J Ophthalmol. 2018;102:1391\u20135.","journal-title":"Br J Ophthalmol"},{"key":"4089_CR31","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/bjophthalmol-2018-312568","volume":"103","author":"AK Denniston","year":"2019","unstructured":"Denniston AK, Lee AY, Lee CS, Crabb DP, Bailey C, Lip PL, et al. United Kingdom Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group: report 4, real-world data on the impact of deprivation on the presentation of diabetic eye disease at hospital services. Br J Ophthalmol. 2019;103:837\u201343.","journal-title":"Br J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04089-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T17:02:02Z","timestamp":1767459722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04089-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4089"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04089-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CD: Consultant for AbbVie, Astellas, Boehringher Ingelheim, Johnson & Johnson, Ocular Therapeutix, and Roche; Research grants from Apellis, Roche, and Topcon; speaker fees and honoraria from Apellis, Bayer, Heidelberg, Roche, and Topcon; MD: Employee of Medisoft; AL: Consultant for Apellis, Eyebio, Johnson & Johnson, Outlook Therapeutics, and Roche; SS: Speaker fees and honoraria from Alimera Sciences, Bayer, and Roche; EF: Travel and speaker funds from Roche; AVRL: Employee of Medisoft; AP: Employee of Roche; LPP: Employee and shareholder of Genentech Inc.; ACR: Employee of Roche; IS: Employee of Roche; PA, GC: Employees of Genentech Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}